{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:18:43Z","timestamp":1794917923015,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ijantimicag.2020.106124","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T22:04:19Z","timestamp":1596146659000},"page":"106124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?"],"prefix":"10.1016","volume":"56","author":[{"given":"A.","family":"Marsot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hraiech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Cassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Daviet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Parzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Papazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Guilhaumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106124_bib0001","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/01.CCM.0000261890.41311.E9","article-title":"Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003","volume":"35","author":"Dombrovskiy","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0002","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.2014.2637","article-title":"Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000\u20132012","volume":"311","author":"Kaukonen","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0003","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0004","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0005","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining Antibiotic Levels in Intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0006","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s00134-017-4782-4","article-title":"Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial","volume":"43","author":"Bloos","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0007","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0008","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/CCM.0b013e3181e96b91","article-title":"A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic\/meta-regression study","volume":"38","author":"Kumar","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0009","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/CCM.0b013e3181eb3ccd","article-title":"Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis","volume":"38","author":"Kumar","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0010","first-page":"597","article-title":"Aminoglycosides\u201450 years on","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0011","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0012","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0013","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00993-19","article-title":"Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori pharmacokinetic\/pharmacodynamic target attainments in individual patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0016","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0017","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/cc9091","article-title":"Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0018","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijantimicag.2016.10.022","article-title":"Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis","volume":"49","author":"Hodiamont","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0019","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QCO.0000000000000494","article-title":"How to optimize antibiotic pharmacokinetic\/pharmacodynamics for Gram-negative infections in critically ill patients","volume":"31","author":"Heffernan","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of \u03b2-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0021","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0022","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2165\/10895960-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance","volume":"48","author":"Adembri","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0023","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.2174\/138920111798808329","article-title":"Using PK\/PD to optimize antibiotic dosing for critically ill patients","volume":"12","author":"Roberts","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0024","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","article-title":"Amikacin in critically ill patients: a review of population pharmacokinetic studies","volume":"56","author":"Marsot","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0025","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0026","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.medmal.2011.07.007","article-title":"Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring","volume":"42","year":"2012","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0027","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0028","article-title":"PK\/PD targets of amikacin and gentamicin in ICU patients","author":"Coste","year":"2019","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0031","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0032","first-page":"639","article-title":"Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy","volume":"72","author":"Llanos-Paez","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0033","first-page":"236","article-title":"Daily dosage of aminoglycosides","volume":"17","author":"Urban","year":"1997","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0034","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40262-013-0036-y","article-title":"Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis","volume":"52","author":"Hennig","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00877-18","article-title":"Population pharmacokinetics of amikacin in adult patients with cystic fibrosis","volume":"62","author":"Illamola","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0036","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01477-06","article-title":"Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers","volume":"51","author":"Bulitta","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0037","series-title":"IDWeek\u24c7 2018","article-title":"Pharmacokinetic\u2013pharmacodynamic (PK-PD) target attainment analyses to support inhaled ME1100 dose selection","author":"Bhavnani","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0038","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00134-014-3276-x","article-title":"Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen","volume":"40","author":"de Montmollin","year":"2014","journal-title":"Intensive Care Med"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2020.106124_bib0039","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1007\/BF01709707","article-title":"Pharmacokinetics of antibiotics in critically ill patients","volume":"16","author":"van Dalen","year":"1990","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/jcrc.2003.50003","article-title":"A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes","volume":"18","author":"Bacopoulou","year":"2003","journal-title":"J Crit Care"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0041","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2018.04.016","article-title":"Predictive performance of a gentamicin population pharmacokinetic model in two Western populations of critically ill patients","volume":"52","author":"Bukkems","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0042","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijantimicag.2017.03.029","article-title":"Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model","volume":"50","author":"Pouzot-Nevoret","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106124_bib0043","series-title":"Aminoglycoside dosing in adults","year":"2018"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:21Z","timestamp":1760377101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920303071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0924857920303071"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106124","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106124"}}